Search

everythinglearnresearchcommunity

for

Search:↓

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

A man developed alopecia areata after starting cancer treatment with vandetanib.

Some leukemia treatments can cause skin reactions similar to keratosis pilaris.

Gefitinib can cause hair and eyebrow darkening.

MK-2206 was safe and effectively blocked AKT signaling in cancer patients, warranting more trials.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

Selumetinib causes fewer and less severe skin issues in children than binimetinib.

New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.

Shrinking skin cancer increases the chance of cancer in nearby lymph nodes.

ETC-159 was safe up to 30 mg, but no tumor shrinkage was seen.

Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.

Gefitinib therapy can cause unusual hair growth on the nose.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

Gefitinib can cause rare scarring hair loss.

Imatinib can cause hair loss due to lichen planopilaris.

Gefitinib can cause slower, finer, brittle, and curly scalp hair.

Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.

A cancer patient developed a type of hair loss after starting a cancer drug called vandetanib.

A man's bald spot grew hair after starting cancer treatment with gefitinib.

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Dabrafenib can cause skin growths and sometimes low-grade skin cancer.

A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.

An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.

Blocking mTORC1 reduces skin tumor growth in mice.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

Photodynamic therapy improved skin issues from sorafenib when other treatments failed.

Upadacitinib may help regrow hair in children with alopecia areata and is generally safe.

Gefitinib can cause hair loss without scarring.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.